Key Takeaways Stelara's patent loss led to a 42.7% sales decline in Q2 2025, putting pressure on J&J's earnings.Medicare Part D redesign is expected to cut J&J's 2025 sales by about $2 billion.J&J faces 62,000 talc lawsuits and China MedTech pressure but maintains growth outlook.Johnson & Johnson (JNJ) faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we discuss the various headwinds tha ...